GGrantIndex
← Leaderboards

Paul B Rosenberg

Johns Hopkins University

Google Scholar ↗PubMed ↗ORCID ↗
$14,116,062
Attributed
$31,119,146
Total exposure
11
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.6M · FY2008–24
$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24

Funding mix

By agency

NIH$31,119,146 · 11

By mechanism

R01$30,580,083 · 10
K08$539,063 · 1

Top collaborators

Most similar at Johns Hopkins University

Same institution · by research overlap

Others in their field

Top investigators on “Alzheimer&Apos”

Research focus

Alzheimer&AposS DiseaseCognitiveResearch PersonnelDementiaRandomizedPharmaceutical PreparationsCognitionPrimary OutcomePlacebosSleepAffectReportingImpaired CognitionCaregiversBrainFda ApprovedSymptomsSafetySecondary OutcomeDouble-Blind MethodDisabilityNeuropsychiatrySite

Grant awards (50)

RCT Targeting Cognition in Early Alzheimer's Disease by Improving Sleep with Trazodone (Rest)$858,987
R01 · FY2024 · AG
RCT Targeting Cognition in Early Alzheimer's Disease by Improving Sleep with Trazodone (Rest)$710,750
R01 · FY2023 · AG
RCT Targeting Cognition in Early Alzheimer's Disease by Improving Sleep withTrazodone (Rest)$99,527
R01 · FY2023 · AG
RCT Targeting Cognition in Early Alzheimer's Disease by Improving Sleep with Trazodone (Rest)$748,283
R01 · FY2022 · AG
Pilot trial of dronabinol adjunctive treatment of agitation in Alzheimer's disease (AD)$992,308
R01 · FY2021 · AG · contact PI
RCT Targeting Cognition in Early Alzheimer's Disease by Improving Sleep with Trazodone (Rest)$785,568
R01 · FY2021 · AG
Circadian rhythm disturbance and agitation in Alzheimer's disease$634,321
R01 · FY2021 · AG · contact PI
Effect of Covid-19 on Caregivers of Persons with Dementia$446,295
R01 · FY2021 · AG · contact PI
Pilot trial of dronabinol adjunctive treatment of agitation in Alzheimer's disease (AD)$997,731
R01 · FY2020 · AG · contact PI
Problem Adaptation Therapy for Mild Cognitive Impairment with Depression$683,153
R01 · FY2020 · AG
Circadian rhythm disturbance and agitation in Alzheimer's disease$656,107
R01 · FY2020 · AG · contact PI
Problem Adaptation Therapy for Mild Cognitive Impairment with Depression$696,395
R01 · FY2019 · AG
Circadian rhythm disturbance and agitation in Alzheimer's disease$650,274
R01 · FY2019 · AG · contact PI
Actigraphic assessment of sleep quality in the A4 trial$324,520
R01 · FY2019 · AG · contact PI
Apathy in Alzheimer's Disease Methyphenidate Trial II (ADMET II)$1,297,999
R01 · FY2018 · AG
Pilot trial of dronabinol adjunctive treatment of agitation in Alzheimer's disease (AD)$997,674
R01 · FY2018 · AG · contact PI
Problem Adaptation Therapy for Mild Cognitive Impairment with Depression$722,853
R01 · FY2018 · AG
Circadian rhythm disturbance and agitation in Alzheimer's disease$650,274
R01 · FY2018 · AG · contact PI
Apathy in Alzheimer's Disease Methyphenidate Trial II (ADMET II)$367,383
R01 · FY2018 · AG
Actigraphic assessment of sleep quality in the A4 trial$324,543
R01 · FY2018 · AG · contact PI
Apathy in Alzheimer's Disease Methyphenidate Trial II (ADMET II)$172,427
R01 · FY2018 · AG
Apathy in Alzheimer's Disease Methyphenidate Trial II (ADMET II)$100,000
R01 · FY2018 · AG
Apathy in Alzheimer's Disease Methyphenidate Trial II (ADMET II)$1,455,745
R01 · FY2017 · AG
Pilot trial of dronabinol adjunctive treatment of agitation in Alzheimer's disease (AD)$996,923
R01 · FY2017 · AG · contact PI
Circadian rhythm disturbance and agitation in Alzheimer's disease$797,636
R01 · FY2017 · AG · contact PI
Problem Adaptation Therapy for Mild Cognitive Impairment with Depression$741,645
R01 · FY2017 · AG
Actigraphic assessment of sleep quality in the A4 trial$324,577
R01 · FY2017 · AG · contact PI
Apathy in Alzheimer's Disease Methyphenidate Trial II (ADMET II)$144,804
R01 · FY2017 · AG
Apathy in Alzheimer's Disease Methyphenidate Trial II (ADMET II)$1,451,083
R01 · FY2016 · AG
Pilot trial of dronabinol adjunctive treatment of agitation in Alzheimer's disease (AD)$1,024,654
R01 · FY2016 · AG · contact PI
Problem Adaptation Therapy for Mild Cognitive Impairment with Depression$772,824
R01 · FY2016 · AG
Actigraphic assessment of sleep quality in the A4 trial$337,189
R01 · FY2016 · AG · contact PI
Apathy in Alzheimer's Disease Methyphenidate Trial II (ADMET II)$100,000
R01 · FY2016 · AG
Apathy in Alzheimer's Disease Methyphenidate Trial II (ADMET II)$1,426,649
R01 · FY2015 · AG
Actigraphic assessment of sleep quality in the A4 trial$362,687
R01 · FY2015 · AG · contact PI
Apathy in Alzheimer's Disease Methyphenidate Trial II (ADMET II)$1,590,989
R01 · FY2014 · AG
Pilot Trial of Carvedilol in Alzheimer's Disease$545,008
R01 · FY2013 · AG
DIADS-3: An RCT of venlafaxine for depression in AD$522,805
R01 · FY2013 · AG · contact PI
Pilot Trial of Carvedilol in Alzheimer's Disease$592,548
R01 · FY2012 · AG
DIADS-3: An RCT of venlafaxine for depression in AD$552,117
R01 · FY2012 · AG · contact PI
A Theoretically Based Memory Training Intervention in Mild Cognitive Impairment$290,839
R01 · FY2012 · AG · contact PI
PET imaging of activated microglia in Alzheimer's Disease$110,829
K08 · FY2012 · AG · contact PI
Pilot Trial of Carvedilol in Alzheimer's Disease$626,271
R01 · FY2011 · AG
DIADS-3: An RCT of venlafaxine for depression in AD$555,730
R01 · FY2011 · AG · contact PI
PET imaging of activated microglia in Alzheimer's Disease$110,829
K08 · FY2011 · AG · contact PI
Apathy in Alzheimer's Disease Methylphenidate Trial$709,569
R01 · FY2010 · AG
PET imaging of activated microglia in Alzheimer's Disease$107,341
K08 · FY2010 · AG · contact PI
Apathy in Alzheimer's Disease Methylphenidate Trial$740,419
R01 · FY2009 · AG
PET imaging of activated microglia in Alzheimer's Disease$105,450
K08 · FY2009 · AG · contact PI
PET imaging of activated microglia in Alzheimer's Disease$104,614
K08 · FY2008 · AG · contact PI